是否atogepant可以作为集群头痛的预防性治疗方法?-从一系列病例中的见解
Catarina Serrão1, Filipa Dourado Sotero1,2,3, Linda Azevedo Kaupilla3
1Department of Neurosciences and Mental Health, Hospital de Santa Maria, ULS Santa Maria, Lisbon, Portugal.
Headache
|October 4, 2025
概括
阿托盖潘特是一种口服CGRP受体对抗剂,显示出对集群头痛 (CH) 预防的前景. 治疗耐药性CH的四名患者经历了每日服用阿托基潘特的缓解,这表明其作为新型预防疗法的潜力.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 集群头痛 (CH) 是一种严重的神经疾病,有效治疗方法有限.
- 素基因相关 (CGRP) 在CH病理生理学中起作用,但抗CGRP单克隆抗体的成功程度有限.
- 现有的CH的预防方案往往是不够的,特别是在慢性和耐火病例.
研究的目的:
- 调查口服CGRP受体对抗剂阿托基潘特 (atogepant) 作为集群头痛预防治疗的疗效.
- 为了评估atogepant在那些对其他疗法没有反应的偶发性和慢性CH患者的有效性.
主要方法:
- 分析了四名患有集群头痛的患者病例系列 (两个是偶发性,两个是慢性).
- 患者每天接受口服阿托基潘特 (60毫克),其中一个病例调整剂量 (30毫克).
- 记录了以前的治疗反应,包括对加尔坎祖马布的治疗.
主要成果:
- 所有四名耐治疗性CH患者都对每天的阿托盖潘特 (60毫克) 产生了积极反应.
- 两例慢性CH病例对皮下加尔干祖马布不耐药,但通过atogepant得到改善.
- 降低阿托基潘特剂量导致头痛复发,在恢复原始剂量后,头痛恢复. 没有报告任何严重不良事件.
结论:
- 这一案例系列表明,每天口服的阿托基潘特可能是集群头痛的可行的预防方案,包括慢性和耐加祖马布的病例.
- 需要通过精心设计的临床试验进行进一步的研究,以确认atogepant在CH的疗效和安全性.
- 了解CH病理生理学中的CGRP信号可能会导致更有针对性的治疗策略.
相关概念视频
Open Angle Glaucoma: Treatment
961
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
961
Angle Closure Glaucoma: Treatment
1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
460
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
460
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
599
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
599
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
583
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
583
Cholinergic Antagonists: Therapeutic Uses
1.3K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.3K


